Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN846 in Refractory Pruritus with Atopic Dermatitis
NCT01605708Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2012
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of REGN846 in pruritus, atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Jun 2012; status: terminated.
02
Drugs
REGN846
03
Conditions
pruritusatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01605708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01605708.